Description:
Background
G-protein-coupled receptors (GPCRs) are pivotal in cell signaling and represent a major target class for drug development. Among them, cannabinoid receptors, especially CB2, play a crucial role in regulating neuroinflammation and immune responses. Current therapeutic options inadequately modulate CB2 activity, limiting effective treatment for neurodegenerative, autoimmune, and chronic pain disorders. There is a strong unmet need for selective, potent compounds capable of precisely targeting CB2 receptors to alleviate these conditions while minimizing side effects.
Technology Description
USC researchers have developed novel sulfonamide-functionalized heterocyclic compounds designed to modulate cannabinoid CB2 receptor signaling. Using ultra-large combinatorial libraries and reliable chemical reactions such as Sulfur Fluoride Exchange (SuFEx), they synthesized diverse triazole- and isoxazole-based molecules. These compounds demonstrate high binding affinity and functional antagonism at CB2, achieving a 55% hit rate in screening assays. This innovative approach provides superior access to new chemical space and improved therapeutic potential compared to traditional drug discovery methods.
Key Advantages
- High Selectivity: Targets CB2 receptors selectively, reducing off-target effects and improving safety profiles.
- Innovative Chemistry: Employs advanced SuFEx reactions enabling rapid, diverse compound generation with robust synthetic routes.
- Proven Efficacy: Demonstrates potent receptor antagonism validated by binding affinity and functional assays.
- Broad Therapeutic Potential: Applicable for treating neurodegenerative diseases, autoimmune disorders, chronic pain, and cancer.
Stage of Development
- Synthesis and in vitro functional assays completed
- Lead compounds identified via virtual screening and biochemical validation
Applications
- Development of novel therapeutics for neurodegenerative diseases such as multiple sclerosis and neuroinflammation
- Treatment of autoimmune disorders by regulating immune responses through CB2 modulation
- Management of chronic pain syndromes with reduced side effects compared to existing cannabinoid treatments
- Potential adjunct therapies for cancers influenced by cannabinoid receptor signaling
Publications
Key Words
- CB2 receptor modulators
- Sulfonamide heterocycles
- GPCR drug discovery
- SuFEx combinatorial chemistry